Dawawale Pharmaceuticals Limited
About Dawawale Pharmaceuticals Limited
Data last updated:
Dawawale Pharmaceuticals Limited is a public limited company based in Noida, Uttar Pradesh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 09 September 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Kanpur, under CIN U24290UP2020PLC134254. Its GSTIN is 09AAHCD9753H1Z6 (Uttar Pradesh). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹44 Lakh. It is led by directors including Gopal Prasad Sinha and Nitin Kumar.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at D – 39 Sector – 10 Gautam Buddha Nagar, Noida, Uttar Pradesh, India – 201301.
As per the financials filed for FY 2023, the company reported a revenue of ₹87.59 Lakh, a decline of 66% compared to the previous year. For the same year it recorded a net profit of ₹22,936 (net margin 0.3%) and EBITDA of ₹1.3 Lakh (EBITDA margin 1.5%).
Company details
Contact details
Dawawale Pharmaceuticals Limited's registered office is in Noida, Uttar Pradesh.
- Registered AddressD – 39 Sector – 10 Gautam Buddha Nagar, Noida, Uttar Pradesh, India – 201301
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Dawawale Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Dawawale Pharmaceuticals Limited, buy the company report.
Financials of Dawawale Pharmaceuticals Limited
FY 2023 filings availableDawawale Pharmaceuticals Limited reported revenue of ₹87.59 Lakh (down 66% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue fell 66% in the latest year. EBITDA fell 52% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹1.3 Lakh | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹22,936 | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 1.5% | ||
| Net Profit Margin | 0.3% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Dawawale Pharmaceuticals Limited, buy the company report.
Board of directors of Dawawale Pharmaceuticals Limited
Dawawale Pharmaceuticals has 3 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gopal Prasad Sinha Also directs: Pavitra Kuber Nidhi Limited, Olex Infrastructure Private Limited | Director | 09 Sep 2020 | 6 Years 2 Months | Current |
| Nitin Kumar Also directs: Shubh Sourya Developers LLP, Shubh Sourya Infrastructure Private Limited, Royal Nest Homes Private Limited and 2 more | Director | 15 Jul 2022 | 4 Years 3 Months | Current |
| Nilam Sinha | Director | 09 Sep 2020 | 6 Years 2 Months | Current |
Legal cases
No court or tribunal cases involving Dawawale Pharmaceuticals Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Dawawale Pharmaceuticals Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Dawawale Pharmaceuticals has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAHCD9753H1Z6 | Uttar Pradesh | Active | 25 Nov 2020 |
| 10AAHCD9753H1ZN | Bihar | Active | 03 Dec 2020 |
To see the full GST registrations and return filing status of Dawawale Pharmaceuticals Limited, buy the company report.
Recent activity
Dawawale Pharmaceuticals Limited has 5 board changes on record since 2020: 3 appointments and 2 cessations. The latest: Bhawna Sinha ceased to be Additional Director on 15 Jul 2022.
Frequently asked questions
Dawawale Pharmaceuticals is an active public limited company based in Noida, Uttar Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 09 September 2020 (6+ years old) and is registered under CIN U24290UP2020PLC134254.
Dawawale Pharmaceuticals has 3 current directors:
- Gopal Prasad Sinha - Director
- Nitin Kumar - Director
- Nilam Sinha - Director
The latest financial statements of Dawawale Pharmaceuticals on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 30 September 2023. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Dawawale Pharmaceuticals is 09AAHCD9753H1Z6, registered in Uttar Pradesh. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 10AAHCD9753H1ZN (Bihar).
The CIN (Corporate Identification Number) of Dawawale Pharmaceuticals is U24290UP2020PLC134254. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dawawale Pharmaceuticals was incorporated on 09 September 2020, making it 6+ years old. It is registered with the Registrar of Companies, Kanpur.
Bhawna Sinha ceased to be Additional Director on 15 Jul 2022. Nitin Kumar was appointed as Director on 15 Jul 2022. Arvind Kumar Sinha ceased to be Director on 22 Jun 2021. Dawawale Pharmaceuticals has 5 board changes on record in total.
The registered office of Dawawale Pharmaceuticals is at D – 39 Sector – 10 Gautam Buddha Nagar, Noida, Uttar Pradesh, India – 201301.
Dawawale Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Dawawale Pharmaceuticals can be reached at its registered office: D – 39 Sector – 10 Gautam Buddha Nagar, Noida, Uttar Pradesh, India – 201301.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
